In this issue of JAMA Otolaryngology–Head & Neck Surgery, Wolf et al1 describe very high survival rates in an unselected cohort of 247 patients with advanced laryngeal cancer. These patients were treated with a program of individualized bioselection. All of us invested in the care of patients with advanced laryngeal cancer must breathe a deep sigh of relief. Only 10 years ago, Hoffman et al,2 in a landmark review of the national cancer database, evaluated the outcome of 158 426 patients with laryngeal cancer. Between the years of 1985 and 2001, the survival rate had gone down. So what has changed?
Johnson JT. Individualized Treatment of Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg. Published online February 02, 2017. doi:10.1001/jamaoto.2016.4298